EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

20 November 2012
EMA/HMPC/560961/2010
Committee on Herbal Medicinal Products (HMPC)

This document was valid from 20 November 2012 until June 2018. It is now superseded by a new version adopted by the HMPC on 05 June 2018 and published on the EMA website.

Discussion in Working Party on Community monographs and Community list (MLWP)	September 2010 November 2010 January 2011 March 2011
Adoption by Committee on Herbal Medicinal Products (HMPC) for release for consultation	31 March 2011
End of consultation (deadline for comments).	15 August 2011
Rediscussion in Working Party on Community monographs and Community list (MLWP)	September 2011 November 2011 January 2012 May 2012
Adoption by Committee on Herbal Medicinal Products (HMPC)	20 November 2012

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional use; *Pelargonium sidoides* DC and/or *Pelargonium reniforme* Curt., radix; Pelargonii radix; pelargonium root

BG (bălgarski): Пеларгониум, корен	LT (lietuvių kalba): Pelargonijų šaknys
CS (čeština): pelargoniový kořen	LV (latviešu valoda): Pelargonijas saknes
DA (dansk): Pelargonierod	MT (malti): Għerq tal-Ġeranju
DE (Deutsch): Pelargoniumwurzel	NL (nederlands): Geranium
EL (elliniká):	PL (polski): Korzeń pelargonii
EN (English): pelargonium root	PT (português): Pelargónio, raiz
ES (espanol): Pelargonio, raíz de	RO (română):
ET (eesti keel): pelargoonijuur	SK (slovenčina): Muškátový koreň
FI (suomi): pelaroonijuur	SL (slovenščina): korenina pelargonije
FR (français): Pélargonium (racine de)	SV (svenska): Pelargonrot
HU (magyar): Muskátligyökér	*IS (íslenska)*:
IT (italiano): Pelargonio radice	*NO (norsk)*: Pelargoniumrot

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Community herbal monograph on *Pelargonium sidoides* DC and/or *Pelargonium reniforme* Curt., radix

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition[1, 2]

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended *Pelargonium sidoides* DC and/or *Pelargonium reniforme* Curt., radix (pelargonium root) i) Herbal substance Not applicable. ii) Herbal preparations a) Liquid extract (DER 1:8-10), extraction solvent ethanol 11% (m/m) b) Dry extract, (DER 4-25:1), extraction solvent ethanol 11% (m/m)

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparations in liquid or solid dosage forms for oral use. The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

[1] The material complies with the Ph. Eur. monograph (ref.: 01/2008:2264).
[2] The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Traditional herbal medicinal product for the symptomatic treatment of common cold. The product is a traditional herbal medicinal product for use in the specified indication exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology Single dose *Adolescents over the age of 12 years, adults and elderly* a) Liquid extract: 1.19-1.25 ml, 3 times daily. b) Dry extract: 20 mg, 3 times daily *Children between 6-12 years* a) Liquid extract: 0.79-0.83 ml, 3 times daily. b) Dry extract: 20 mg, 2 times daily The use in children under 6 years of age is not recommended (see section 4.4 'Special warnings and precautions for use'). **Duration of use** If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. **Method of administration** Oral use.

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to the active substance(s).

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children under 6 years of age has not been established due to lack of adequate data. Hepatotoxicity and hepatitis cases were reported in association with the administration of the medicinal product. In case signs of hepatotoxicity occur, the administration of the medicinal product should be stopped immediately and a medical doctor should be consulted. If the symptoms worsen during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted. For liquid extracts containing ethanol, the appropriate labelling for ethanol, taken from the 'Guideline on excipients in the label and package leaflet of medicinal products for human use', must be included.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Pregnancy and lactation

Well-established use	Traditional use
	No fertility data available. Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	Mild gastrointestinal complaints (diarrhoea, epigastric discomfort, nausea or vomiting, dysphagia), mild nasal and gingival bleeding and allergic reactions have been reported. The frequency was very rare. Hepatotoxicity has been reported. The frequency is not known. If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	No case of overdose has been reported.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity are not available.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation / last revision

20 November 2012